Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 7Retatrutide (LY3437943) literatureBehavioural brain research · Animal study · Preclinical2026

Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.

Retatrutide may partially improve cognitive deficits in diabetic rats, but its relevance to human diabetes remains unclear.

Read at Behavioural brain researchAdd to compare

Where it sits

this study against the rest of the retatrutide (ly3437943) corpus
4
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
3
Reviews

Summary and findings

The study assessed the effects of Retatrutide on learning and memory in streptozotocin-induced diabetic male rats. Retatrutide reduced blood glucose levels and partially improved cognitive performance in the Morris Water Maze and Passive Avoidance tests. It also reduced hippocampal TNF-α levels but did not prevent diabetes-associated weight loss.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Retatrutide-treated diabetic rats showed preserved overall Morris Water Maze performance relative to untreated diabetic rats.Preclinical2026

Abstract

The authors’ words, as Behavioural brain research supplied them

Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has shown strong metabolic efficacy, but its effects on diabetes-associated cognitive dysfunction remain unclear. The present study investigated whether Retatrutide attenuates learning- and memory-related impairments in a streptozotocin-induced, insulin-deficient diabetic rat model. Male Sprague-Dawley rats were allocated to four groups: control (C), streptozotocin-induced diabetic (STZ), streptozotocin-induced diabetic treated with Retatrutide (STZR), and Retatrutide alone (R). Diabetes was induced with streptozotocin, and spatial learning and memory were assessed using the Morris Water Maze and Passive Avoidance tests. Metabolic parameters were monitored, while hippocampal cytokine levels (IL-1β, TNF-α), BDNF, CREB, and AKT mRNA expression, Tau protein levels, and cortical and hippocampal histopathology were evaluated using biochemical, molecular, and histological methods. Streptozotocin-induced diabetes produced persistent hyperglycaemia, marked body weight loss, and impaired behavioural performance, particularly prolonged escape latencies in the Morris Water Maze and a selective short-term Passive Avoidance deficit. Retatrutide reduced blood glucose levels but did not prevent diabetes-associated weight loss. In behavioural testing, Retatrutide-treated diabetic rats showed preserved overall Morris Water Maze performance relative to untreated diabetic rats and a limited, task-dependent attenuation of short-term avoidance deficits rather than complete normalisation across all memory measures. These effects were accompanied by a significant reduction in hippocampal TNF-α, a non-significant trend toward lower IL-1β, and partial preservation of cortical and hippocampal cytoarchitecture. Retatrutide alone did not improve behavioural performance beyond control levels, although BDNF and CREB mRNA expression were increased in the non-diabetic Retatrutide group. These findings indicate that Retatrutide is associated with a partial attenuation of streptozotocin-induced behavioural and neuroinflammatory alterations in male rats. The observed effects are consistent with actions extending beyond glycaemic control alone, although direct central exposure of Retatrutide was not established in the present study. Further studies in insulin-resistant and type 2 diabetes-like models are needed to clarify the underlying mechanisms and translational relevance.

Background

Diabetes mellitus is known to cause cognitive impairment and neurodegenerative changes, often linked to hyperglycemia-driven neuroinflammation. Retatrutide, a GIP/GLP-1/glucagon receptor agonist, has demonstrated metabolic benefits, but its impact on cognitive dysfunction in diabetes is not well understood. This study explores Retatrutide's potential to mitigate cognitive deficits in a diabetic rat model.

Methods

The study used male Sprague-Dawley rats divided into four groups: control, diabetic, diabetic treated with Retatrutide, and Retatrutide alone. Diabetes was induced using streptozotocin, and cognitive function was assessed via the Morris Water Maze and Passive Avoidance tests. Metabolic parameters and various biochemical markers were also evaluated.

Results

Retatrutide reduced blood glucose levels in diabetic rats but did not prevent weight loss. In cognitive tests, Retatrutide-treated diabetic rats showed preserved performance in the Morris Water Maze and partial improvement in Passive Avoidance deficits. Retatrutide also reduced hippocampal TNF-α levels and partially preserved cortical and hippocampal structure.

Interpretation

The findings suggest Retatrutide may have benefits beyond glycemic control, potentially attenuating some cognitive deficits associated with diabetes. However, the clinical significance is uncertain due to the study's animal model and lack of direct evidence of central Retatrutide exposure. Further research is needed to explore these effects in humans and other diabetes models.

Key findings

  • Retatrutide reduced blood glucose levels in diabetic rats.
  • Retatrutide-treated diabetic rats showed preserved Morris Water Maze performance.
  • Retatrutide did not prevent diabetes-associated weight loss.
  • Hippocampal TNF-α levels were significantly reduced in Retatrutide-treated rats.
  • Retatrutide alone increased BDNF and CREB mRNA expression in non-diabetic rats.

Limitations

  • animal model, not human data
  • direct central exposure of Retatrutide not established
  • effects not fully normalized across all memory measures
  • potential translational relevance not confirmed

Elsewhere in the Retatrutide (LY3437943) corpus

DRetatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.BMJ (Clinical research ed.) · 2026AComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2026 · n=99791 · Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce 13.1-14.6% weight loss; very low to low certainty.reviewDRetatrutide fact check: Has a man died after taking the unapproved weight loss jab?BMJ (Clinical research ed.) · 2026DMedical Treatments for Obesity: What Does the Future Have in Store?The Journal of clinical endocrinology and metabolism · 2026 · Retatrutide produced weight reductions exceeding 25%.reviewDBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · Not reported in abstract.reviewDBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026